Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | LTK | P29376 | 1/20 | 0.39 |
| ▸ | GRK5 | P34947 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9413252 | 0.74 | KDR (0.56) | KDRCHEK1DAPK3PRKD3MAP4K4 | |
| SCHEMBL21709620 | 0.74 | CHEK1 (0.36) | KDRCHEK1DAPK3PRKD3MAP4K4 | |
| SCHEMBL795294 | 0.72 | DRD1 (0.49) | KDRCHEK1DAPK3PRKD3MAP4K4 | |
| SCHEMBL30159359 | 0.72 | DRD1 (0.49) | KDRCHEK1DAPK3PRKD3MAP4K4 | |
| SCHEMBL17041864 | 0.72 | AKT1S1 (0.42) | KDRCHEK1DAPK3PRKD3MAP4K4 | |
| SCHEMBL5635227 | 0.69 | UHRF1 (0.49) | KDRCHEK1DAPK3PRKD3MAP4K4 | |
| SCHEMBL23085803 | 0.69 | CHEK1 (0.33) | KDRCHEK1DAPK3PRKD3MAP4K4 | |
| SCHEMBL1368910 | 0.65 | NNMT (0.35) | NNMT | |
| SCHEMBL22679489 | 0.65 | ADRA2A (0.42) | — | |
| SCHEMBL3088390 | 0.64 | KDM4E (0.34) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8912330-B2 | Azaindole derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2014-12-11 | — | — | US | disclosed |
| US-8846664-B2 | Pyrazinopyrazines and derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | KDR 662/4885CHEK1 349/4885DAPK3 401/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | KDR 543/4885CHEK1 242/4885DAPK3 312/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | KDR 504/4885CHEK1 275/4885DAPK3 302/4885 |
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | MAP3K5, MAP3K15, MAP4K2 | KDR 1029/4885CHEK1 281/4885DAPK3 133/4885 |
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ABL1, CDKN1A, MAP3K13 | KDR 615/4885CHEK1 199/4885DAPK3 163/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | KDR 662/4885CHEK1 349/4885DAPK3 401/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | KDR 662/4885CHEK1 349/4885DAPK3 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.